Bruce Charles Baguley

Bruce Charles Baguley's AcademicInfluence.com Rankings

Law

#2000

World Rank

#2488

Historical Rank

Common Law

#62

World Rank

#69

Historical Rank

International Law

#311

World Rank

#406

Historical Rank

law Degrees

Bruce Charles Baguley

Biology

#6198

World Rank

#8863

Historical Rank

Biochemistry

#773

World Rank

#877

Historical Rank

biology Degrees

Download Badge

Law
Biology

Bruce Charles Baguley's Degrees

PhD Biochemistry University of Melbourne
Bachelors Biochemistry University of Melbourne

Why Is Bruce Charles Baguley Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Bruce Charles Baguley's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Disrupting tumour blood vessels (2005) (873)
Quenching of DNA-ethidium fluorescence by amsacrine and other antitumor agents: a possible electron-transfer effect. (1984) (557)
Signaling Pathways in Melanogenesis (2016) (553)
Multiple Drug Resistance Mechanisms in Cancer (2010) (429)
Potential antitumor agents. 59. Structure-activity relationships for 2-phenylbenzimidazole-4-carboxamides, a new class of "minimal" DNA-intercalating agents which may not act via topoisomerase II. (1990) (282)
Epigenetic regulation in human melanoma: past and future (2015) (217)
A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. (1984) (190)
Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. (1991) (183)
Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. (1991) (182)
Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes (2000) (180)
Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs (2000) (180)
Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. (1987) (175)
In vitro antitumour and hepatotoxicity profiles of Au(I) and Ag(I) bidentate pyridyl phosphine complexes and relationships to cellular uptake. (2008) (166)
Potenial antitumor agents. 28. Deoxyribonucleic acid polyintercalating agents. (1978) (165)
Antivascular therapy of cancer: DMXAA. (2003) (164)
Potential antitumor agents. 34. Quantitative relationships between DNA binding and molecular structure for 9-anilinoacridines substituted in the anilino ring. (1981) (156)
Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma. (2014) (153)
A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types (2011) (152)
Differences in the carcinogenic evaluation of glyphosate between the International Agency for Research on Cancer (IARC) and the European Food Safety Authority (EFSA) (2016) (151)
Blood flow failure as a major determinant in the antitumor action of flavone acetic acid. (1989) (150)
Papulacandin B: an inhibitor of glucan synthesis in yeast spheroplasts. (1979) (138)
A mathematical model for analysis of the cell cycle in cell lines derived from human tumors (2003) (134)
Potential antitumor agents. 57. 2-Phenylquinoline-8-carboxamides as "minimal" DNA-intercalating antitumor agents with in vivo solid tumor activity. (1989) (132)
Dual topoisomerase I/II inhibitors in cancer therapy. (2003) (131)
DNA-directed alkylating agents. 6. Synthesis and antitumor activity of DNA minor groove-targeted aniline mustard analogues of pibenzimol (Hoechst 33258) (1994) (129)
Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent (2003) (127)
The interaction of ethidium with synthetic double-stranded polynucleotides at low ionic strength (1978) (127)
Emerging Role of Long Non-Coding RNA SOX2OT in SOX2 Regulation in Breast Cancer (2014) (126)
Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (2002) (124)
Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents. (1999) (122)
Structure of a Mammalian Serine tRNA (1968) (116)
Early stages of the apoptotic pathway in plant cells are reversible (1998) (115)
Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. (2009) (115)
Nucleolar damage correlates with neurotoxicity induced by different platinum drugs (2001) (112)
Disrupting established tumor blood vessels (2010) (112)
Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice. (1991) (110)
DNA intercalating anti-tumour agents. (1991) (108)
Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. (1998) (107)
Potential antitumor agents. 51. Synthesis and antitumor activity of substituted phenazine-1-carboxamides. (1987) (107)
Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours. (1987) (106)
Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo. (1989) (106)
Potential antitumor agents. 43. Synthesis and biological activity of dibasic 9-aminoacridine-4-carboxamides, a new class of antitumor agent. (1984) (94)
Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. (1999) (94)
Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation. (1999) (93)
5,6-Dimethylxanthenone-4-Acetic Acid in the Treatment of Refractory Tumors: a Phase I Safety Study of a Vascular Disrupting Agent (2006) (92)
Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors. (1997) (91)
Multidrug resistance in cancer. (2010) (90)
Synthesis, antitumor activity, and DNA binding properties of a new derivative of amsacrine, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino) phenylamino]-4-acridinecarboxamide. (1984) (89)
Interaction of the antitumor drug 4'-(9-acridinylamino)methanesulfon-m-anisidide and related acridines with nucleic acids. (1981) (89)
Evidence for the production of nitric oxide by activated macrophages treated with the antitumor agents flavone-8-acetic acid and xanthenone-4-acetic acid. (1990) (88)
Induction of natural killer cell activity by the antitumour compound flavone acetic acid (NSC 347 512). (1987) (88)
Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. (1999) (87)
Topoisomerase II enzymes and mutagenicity (1994) (86)
Potential antitumor agents. 44. Synthesis and antitumor activity of new classes of diacridines: importance of linker chain rigidity for DNA binding kinetics and biological activity. (1985) (85)
Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474). (2011) (84)
Existence of an extended series of antitumor compounds which bind to deoxyribonucleic acid by nonintercalative means. (1980) (83)
Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. (1994) (82)
A Gene Expression Signature of Invasive Potential in Metastatic Melanoma Cells (2009) (82)
Comparison of in vitro activity of cytotoxic drugs towards human carcinoma and leukaemia cell lines. (1986) (82)
From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives. (1996) (81)
Mutagenic properties of topoisomerase-targeted drugs. (1998) (80)
Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). (1994) (80)
Bis(phenazine-1-carboxamides): structure-activity relationships for a new class of dual topoisomerase I/II-directed anticancer drugs. (2000) (79)
Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma. (2006) (79)
Synthesis and cytotoxic activity of 7-oxo-7H-dibenz[f,ij]isoquinoline and 7-oxo-7H-benzo[e]perimidine derivatives. (2001) (78)
Review of high‐dose intravenous vitamin C as an anticancer agent (2014) (77)
Induction of tumour necrosis factor-α by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (2004) (76)
Selective toxicity of nitracrine to hypoxic mammalian cells. (1984) (75)
Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice (2004) (75)
Keeping abreast with long non-coding RNAs in mammary gland development and breast cancer (2014) (74)
Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells (2011) (72)
Potential antitumor agents. 46. Structure-activity relationships for acridine monosubstituted derivatives of the antitumor agent N-[2-(dimethylamino)ethyl]-9-aminoacridine-4-carboxamide. (1986) (72)
Potential antitumor agents. 54. Chromophore requirements for in vivo antitumor activity among the general class of linear tricyclic carboxamides. (1988) (72)
Mechanisms of tumor vascular shutdown induced by 5,6‐dimethylxanthenone‐4‐acetic acid (DMXAA): Increased tumor vascular permeability (2005) (70)
Effect of flavone acetic acid on Lewis lung carcinoma: evidence for an indirect effect. (1988) (69)
Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects. (1997) (69)
Modelling cell death in human tumour cell lines exposed to the anticancer drug paclitaxel (2004) (69)
The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice (2002) (69)
DNA-directed alkylating agents. 1. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the reactivity of the mustard. (1990) (68)
Potential antitumor agents. 35. Quantitative relationships between antitumor (L1210) potency and DNA binding for 4'-(9-acridinylamino)methanesulfon-m-anisidide analogues. (1981) (67)
Substrate specificity of adenine-specific transfer RNA methylase in normal and leukemic tissues. (1968) (67)
Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug. (1997) (66)
Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor alpha on colon 38 tumours in mice. (1989) (65)
Heterogeneity of expression of epithelial–mesenchymal transition markers in melanocytes and melanoma cell lines (2013) (64)
Synthesis and antitumor activity of some indeno[1,2-b]quinoline-based bis carboxamides. (2000) (64)
Potential antitumor agents. 49. 5-substituted derivatives of N-[2-(dimethylamino)ethyl]-9-aminoacridine-4-carboxamide with in vivo solid-tumor activity. (1987) (62)
ZFAS1: a long noncoding RNA associated with ribosomes in breast cancer cells (2016) (62)
Pharmacokinetics and pharmacodynamics of chlorambucil delivered in parenteral emulsion. (2008) (62)
Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. (1994) (61)
Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. (1997) (59)
Mechanisms of action of DNA intercalating acridine-based drugs: how important are contributions from electron transfer and oxidative stress? (2003) (59)
Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II. (1988) (59)
Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. (1995) (59)
Nonintercalative DNA-binding antitumour compounds (1982) (58)
Thalidomide Pharmacokinetics and Metabolite Formation in Mice, Rabbits, and Multiple Myeloma Patients (2004) (58)
Multiple patterns of resistance of human leukemia cell sublines to amsacrine analogues. (1990) (58)
DMXAA: an antivascular agent with multiple host responses. (2002) (57)
In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II (2002) (56)
Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). (2001) (56)
Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity. (1998) (55)
Potential antitumor agents. 29. Quantitative structure-activity relationships for the antileukemic bisquaternary ammonium heterocycles. (1979) (54)
Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth (2015) (54)
MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and rapamycin sensitivity (2010) (54)
DNA-directed alkylating agents. 5. Acridinecarboxamide derivatives of (1,2-diaminoethane)dichloroplatinum(II). (1992) (52)
Antitumour activity of substituted 9-anilinoacridines--comparison of in vivo and in vitro testing systems. (1981) (52)
Potential antitumor agents. 56. "Minimal" DNA-intercalating ligands as antitumor drugs: phenylquinoline-8-carboxamides. (1988) (52)
Metabolism of Thalidomide in Liver Microsomes of Mice, Rabbits, and Humans (2004) (51)
Potential antitumor agents. 63. Structure-activity relationships for side-chain analogues of the colon 38 active agent 9-oxo-9H-xanthene-4-acetic acid. (1991) (50)
Antitumor activity of XR5944, a novel and potent topoisomerase poison (2001) (50)
The use of human cancer cell lines as a primary screening system for antineoplastic compounds. (1984) (49)
Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer. (1995) (49)
Differential actions of aclarubicin and doxorubicin: the role of topoisomerase I. (1997) (49)
5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA): a New Biological Response Modifier for Cancer Therapy (2002) (49)
Enhancement of in vitro cytotoxicity of mouse peritoneal exudate cells by flavone acetic acid (NSC 347512). (1988) (49)
Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs. (2001) (49)
Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs (2000) (49)
Optimization of the formation of embedded multicellular spheroids of MCF-7 cells: How to reliably produce a biomimetic 3D model. (2016) (49)
Modelling cell population growth with applications to cancer therapy in human tumour cell lines. (2004) (48)
The specificity of transfer ribonucleic acid methylases from rat liver. (1968) (48)
Positioning of the carboxamide side chain in 11-oxo-11H-indeno[1,2-b]quinolinecarboxamide anticancer agents: effects on cytotoxicity. (2001) (47)
Potential antitumor agents. 55. 6-Phenylphenanthridine-4-carboxamides: a new class of DNA-intercalating antitumor agents. (1988) (46)
AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells (2020) (46)
Mutagenicity of anticancer drugs that inhibit topoisomerase enzymes. (1996) (46)
Extravascular transport of the DNA intercalator and topoisomerase poison N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide (DACA): diffusion and metabolism in multicellular layers of tumor cells. (2001) (45)
Light-induced breakdown of flavone acetic acid and xanthenone analogues in solution. (1990) (45)
Thalidomide increases both intra-tumoural tumour necrosis factor-α production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid (1999) (45)
Design of NDA Intercalators To Overcome Topoisomerase II-Mediated Multidurg Resistance (1990) (45)
The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor. (2001) (44)
Major changes in chromatin condensation suggest the presence of an apoptotic pathway in plant cells. (1998) (44)
Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors (2013) (44)
DNA-directed alkylating agents. 2. Synthesis and biological activity of platinum complexes linked to 9-anilinoacridine. (1990) (44)
Microculture-based chemosensitivity testing: a feasibility study comparing freshly explanted human melanoma cells with human melanoma cell lines. (1992) (43)
Synthesis, biological evaluation and molecular modelling of sulfonohydrazides as selective PI3K p110α inhibitors (2007) (43)
Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines. (2003) (43)
Experimental solid tumour activity ofN-[2-(dimethylamino)ethyl]-acridine-4-carboxamide (2004) (43)
Radiosensitivity of new and established human melanoma cell lines: comparison of [3H]thymidine incorporation and soft agar clonogenic assays. (1994) (42)
Strategies to Maximize Liposomal Drug Loading for a Poorly Water-soluble Anticancer Drug (2014) (42)
Temporal aspects of the action of ASA404 (vadimezan; DMXAA) (2010) (42)
Pharmacokinetics and pharmacodynamics of chlorambucil delivered in long-circulating nanoemulsion (2009) (41)
Phase I study of the cytotoxic agent N -[2-(dimethylamino)ethyl]acridine-4-carboxamide (1999) (40)
In vitro modelling of human tumour behaviour in drug discovery programmes. (2004) (39)
Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridin-(5H)ones. (2005) (39)
Selectivity of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide towards Lewis lung carcinoma and human tumour cell lines in vitro. (1989) (38)
Synthesis and cytotoxic activity of carboxamide derivatives of benzimidazo[2,1-a]isoquinoline and pyrido[3',2':4,5]imidazo[2,1-a]isoquinoline. (2000) (37)
Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines (2015) (37)
DNA-directed alkylating agents. 3. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the length of the linker chain. (1990) (37)
Potential antitumor agents. 62. Structure-activity relationships for tricyclic compounds related to the colon tumor active drug 9-oxo-9H-xanthene-4-acetic acid. (1991) (37)
Post-insertion of poloxamer 188 strengthened liposomal membrane and reduced drug irritancy and in vivo precipitation, superior to PEGylation. (2015) (37)
Immunomodulatory Actions of Xanthenone Anticancer Agents (1997) (37)
Tumor stem cell niches: a new functional framework for the action of anticancer drugs. (2006) (36)
Thalidomide metabolites in mice and patients with multiple myeloma. (2003) (36)
Multiple Isoforms of ANRIL in Melanoma Cells: Structural Complexity Suggests Variations in Processing (2017) (36)
Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit (1999) (35)
Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice. (1992) (35)
Thiolytic cleavage of the anti-tumour compound 4'-(9-acridinylamino)-methanesulphon-m-anisidine (m-AMSA, NSC 156 303) in blood. (1977) (35)
The use of vascularised spheroids to investigate the action of flavone acetic acid on tumour blood vessels. (1990) (34)
Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). (1997) (34)
Ring-substituted 11-oxo-11H-indeno[1,2-b]quinoline-6-carboxamides with similar patterns of cytotoxicity to the dual topo I/II inhibitor DACA. (1999) (34)
Potential antitumor agents. 60. Relationships between structure and in vivo colon 38 activity for 5-substituted 9-oxoxanthene-4-acetic acids. (1990) (34)
Evidence for the Existence of Triple-Negative Variants in the MCF-7 Breast Cancer Cell Population (2014) (34)
Modelling the flow of cytometric data obtained from unperturbed human tumour cell lines: Parameter fitting and comparison (2005) (33)
Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents. (2001) (33)
MITF and PAX3 Play Distinct Roles in Melanoma Cell Migration; Outline of a “Genetic Switch” Theory Involving MITF and PAX3 in Proliferative and Invasive Phenotypes of Melanoma (2013) (33)
Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice. (1990) (33)
Mechanism of resistance of noncycling mammalian cells to 4'-(9-acridinylamino)methanesulfon-m-anisidide: comparison of uptake, metabolism, and DNA breakage in log- and plateau-phase Chinese hamster fibroblast cell cultures. (1988) (32)
Potential antitumor agents. 64. Synthesis and antitumor evaluation of dibenzo[1,4]dioxin-1-carboxamides: a new class of weakly binding DNA-intercalating agents. (1992) (32)
Phase I trial of the amsacrine analogue 9-[( 2-methoxy-4-[(methylsulfonyl)amino]-phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921). (1988) (32)
Novel pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors: Exploring the benzenesulfonohydrazide SAR. (2012) (32)
Identification and reactivity of the major metabolite (ß-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans (2001) (31)
Anticancer drug sensitivity profiles of new and established melanoma cell lines. (1993) (30)
Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid (2004) (30)
The Role of the Hippo Pathway in Melanocytes and Melanoma (2013) (30)
The potential of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide]to circumvent three multidrug-resistance phenotypes in vitro (1997) (30)
Transport of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide by human intestinal Caco-2 cells. (2005) (29)
Activin is a potent growth suppressor of epithelial ovarian cancer cells. (2009) (28)
Metabolism of N -[2-(dimethylamino)ethyl]acridine-4-carboxamide in cancer patients undergoing a phase I clinical trial (1999) (28)
Potential of DMXAA combination therapy for solid tumors (2002) (28)
In vivo effects of chlorophyllin on the antitumour agent cyclophosphamide (1997) (28)
Redox chemistry of the 9-anilinoacridine class of antitumor agents. (1987) (28)
Verapamil as a co-mutagen in the Salmonella/mammalian microsome mutagenicity test. (1988) (28)
Potential antitumor agents. 39. Anilino ring geometry of amsacrine and derivatives: relationship to DNA binding and antitumor activity. (1983) (28)
In vitro methylation of yeast serine transfer ribonucleic acid. (1970) (28)
Microfluidic Preparation of Chlorambucil Nanoemulsion Formulations and Evaluation of Cytotoxicity and Pro-Apoptotic Activity in Tumor Cells (2008) (27)
The CDKN2A G500 Allele Is More Frequent in GBM Patients with No Defined Telomere Maintenance Mechanism Tumors and Is Associated with Poorer Survival (2011) (27)
Structure-activity relationships for thiolytic cleavage rates of antitumor drugs in the 4'-(9-acridinylamino)methanesulfonanilide series. (1976) (27)
Plasma nitrate clearance in mice: modeling of the systemic production of nitrate following the induction of nitric oxide synthesis (2004) (27)
Potential antitumor agents. 52. Carbamate analogues of amsacrine with in vivo activity against multidrug-resistant P388 leukemia. (1987) (27)
Multidrug resistance and mutagenesis. (1993) (26)
Effect of flavone acetic acid (NSC 347,512) on splenic cytotoxic effector cells and their role in tumour necrosis. (1989) (26)
A BRIEF HISTORY OF CANCER CHEMOTHERAPY (2002) (26)
Antitumour activity of the novel immune modulator 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice lacking the interferon-gamma receptor. (1998) (26)
Endocrine Therapy of Estrogen Receptor-Positive Breast Cancer Cells: Early Differential Effects on Stem Cell Markers (2017) (26)
Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors. (2012) (26)
DNA-directed alkylating agents. 4. 4-anilinoquinoline-based minor groove directed aniline mustards. (1991) (26)
A comparison of 1-methyladenine-containing sequences in transfer ribonucleic acid from yeast and from rat liver. (1969) (26)
The Morphological Effects Of The Anti‐Tumor Agents Flavone Acetic Acid And 5,6‐Dimethyl Xanthenone Acetic Acid On The Colon 38 Mouse Tumor (1994) (25)
Chemoprotection by 9-aminoacridine derivatives against the cytotoxicity of topoisomerase II-directed drugs. (1989) (25)
Anticancer drug development (2002) (25)
Variable Expression of GLIPR1 Correlates with Invasive Potential in Melanoma Cells (2013) (25)
Comparative studies of mutagenic, DNA binding and antileukaemic properties of 9-anilinoacridine derivatives and related compounds. (1983) (25)
Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide (2000) (25)
Subcellular distribution and photocytotoxicity of aluminium phthalocyanines and haematoporphyrin derivative in cultured human meningioma cells. (1996) (25)
Cytokine induction and therapeutic synergy with interleukin-2 against murine renal and colon cancers by xanthenone-4-acetic acid derivatives. (1992) (25)
Evidence That GRIN2A Mutations in Melanoma Correlate with Decreased Survival (2014) (25)
Inhibition of growth of primary human tumour cell cultures by a 4-anilinoquinazoline inhibitor of the epidermal growth factor receptor family of tyrosine kinases. (1998) (25)
Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or -resistant forms of topoisomerase II: use of computer simulations in new drug development. (1992) (25)
The relationship between frameshift mutagenicity and DNA-binding affinity in a series of acridine-substituted derivatives of the experimental antitumour drug 4'-(9-acridinylamino)methanesulphonanilide (AMSA). (1981) (25)
Modelling the flow cytometric data obtained from unperturbed human tumour cell lines: Parameter fitting and comparison (2005) (24)
Studies on the metabolism of the novel antitumor agent [N-methyl-11C]N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trials. (1997) (24)
Induction of tumour necrosis factor and interferon-gamma in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites. (2004) (24)
The interaction of DNA-targeted platinum phenanthridinium complexes with DNA in human cells. (2001) (24)
Flavone acetic acid (FAA) with recombinant interleukin-2 (TIL-2) in advanced malignant melanoma. II: Induction of nitric oxide production. (1992) (24)
Paclitaxel induces nucleolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity (2003) (24)
Divergent activity of derivatives of amsacrine (m-AMSA) towards Lewis lung carcinoma and P388 leukaemia in mice. (1983) (23)
The Regulatory Role of Long Noncoding RNAs in Cancer Drug Resistance. (2016) (23)
Synthesis of substituted indeno[1,2-b]quinoline-6-carboxamides, [1]benzothieno[3,2-b]quinoline-4-carboxamides and 10H-quindoline-4-carboxamides: evaluation of structure-activity relationships for cytotoxicity. (2000) (23)
Synthesis and cytotoxic activity of N-[(alkylamino)alkyl]carboxamide derivatives of 7-oxo-7H-benz[de]anthracene, 7-oxo-7H-naphtho[1,2,3-de]quinoline, and 7-oxo-7H-benzo[e]perimidine. (2005) (23)
Fractionation of amino acid acceptor ribonucleic acid. II. (1965) (23)
Potential antitumor agents. 45. Synthesis, DNA-binding interaction, and biological activity of triacridine derivatives. (1986) (23)
Potential antitumor agents. 40. Orally active 4,5-disubstituted derivatives of amsacrine. (1984) (23)
Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice (2004) (23)
Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid. (1998) (22)
In vitro assessment ofN-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance (2004) (22)
Aniline mustard analogues of the DNA-intercalating agent amsacrine: DNA interaction and biological activity. (1997) (22)
Population Pharmacokinetic-Pharmacodynamic Model of the Vascular-Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid in Cancer Patients (2008) (22)
Radiation-induced cell cycle delays and p53 status of early passage melanoma cell lines. (2001) (22)
Optimization of Weight Ratio for DSPE-PEG/TPGS Hybrid Micelles to Improve Drug Retention and Tumor Penetration (2018) (22)
Mechanism of cytotoxicity of N -[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II (1999) (22)
Evidence that phospholipase C is involved in the antitumour action of NSC768313, a new thieno[2,3-b]pyridine derivative (2016) (22)
Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours (2007) (21)
Stimulation of macrophage tumouricidal activity by 5,6-dimethyl-xanthenone-4-acetic acid, a potent analogue of the antitumour agent flavone-8-acetic acid. (1992) (21)
Plasma pharmacokinetics of N -[2-(dimethylamino)ethyl]acridine-4-carboxamide in a phase I trial (1999) (21)
PAX3 knockdown in metastatic melanoma cell lines does not reduce MITF expression (2011) (21)
Analysis of the TGFβ functional pathway in epithelial ovarian carcinoma (2001) (21)
Hormone Resistance in Two MCF-7 Breast Cancer Cell Lines is Associated with Reduced mTOR Signaling, Decreased Glycolysis, and Increased Sensitivity to Cytotoxic Drugs (2014) (21)
The recovery of immune responsiveness after treatment with cyclophosphamide. (1971) (21)
Application of fluorescence in situ hybridisation to study the relationship between cytotoxicity, chromosome aberrations, and changes in chromosome number after treatment with the topoisomerase II inhibitor amsacrine (1996) (21)
Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines (2012) (21)
NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). (2003) (20)
Potential antitumor agents. 38. 3-substituted 5-carboxamido derivatives of amsacrine. (1983) (20)
Comparison of the in vivo and in vitro antileukemic activity of monosubstituted derivatives of 4'-(9-acridinylamino)methanesulfon-m-anisidide. (1982) (20)
Interaction of the nonintercalative antitumour drugs SN-6999 and SN-18071 with DNA: influence of ligand structure on the binding specificity. (1987) (20)
Electron-deficient DNA-intercalating agents as antitumor drugs: aza analogues of the experimental clinical agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. (1994) (20)
Relationships between Signaling Pathway Usage and Sensitivity to a Pathway Inhibitor: Examination of Trametinib Responses in Cultured Breast Cancer Lines (2014) (20)
Dimeric analogues of non-cationic tricyclic aromatic carboxamides are a new class of cytotoxic agents. (1999) (19)
Comparison of the effects of genistein and amsacrine on leukemia cell proliferation. (1994) (19)
Potential antitumor agents. 34. Quantitative relationships between DNA binding and molecular structure for 9-anilinoacridines substituted in the anilino ring (1981) (19)
Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice (2001) (19)
Heterogeneity of Phenotype in Breast Cancer Cell Lines (2011) (19)
Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) (2001) (19)
Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide (2002) (19)
Cell cycle times of short-term cultures of brain cancers as predictors of survival (2008) (19)
Isolation of the trinucleotide pppGpCpU from reovirus. (1970) (18)
Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer (2020) (18)
Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) (2007) (18)
Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial (2007) (18)
Synthesis and biological evaluation of novel phosphatidylinositol 3-kinase inhibitors: Solubilized 4-substituted benzimidazole analogs of 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474). (2013) (18)
FRACTIONATION OF AMINO ACID ACCEPTOR RIBONUCLEIC ACIDS ON DIETHYLAMINOETHYL-CELLULOSE COLUMNS. (1965) (18)
Potentiation by phenylbisbenzimidazoles of cytotoxicity of anticancer drugs directed against topoisomerase II. (1990) (18)
Plasma half-life of cytosine arabinoside in patients with leukaemia--the effect of uridine. (1975) (18)
Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions. (1999) (18)
Resistance of cultured Lewis lung carcinoma cell lines to tiazofurin. (1987) (18)
Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer. (1991) (17)
Phenazine-1-carboxamides: structure-cytotoxicity relationships for 9-substituents and changes in the H-bonding pattern of the cationic side chain. (2006) (17)
Nitric oxide production in endotoxin-resistant C3H/HeJ mice stimulated with flavone-8-acetic acid and xanthenone-4-acetic acid analogues. (1992) (17)
Synthesis and anti-tumour activity of topologically-related analogues of flavoneacetic acid. (1989) (17)
Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, 1994: PHARMACOKINETIC/CYTOKINETIC PRINCIPLES IN THE CHEMOTHERAPY OF SOLID TUMOURS (1995) (17)
Inhibition of T4 bacteriophage yield by 9-anilinoacridines; comparison with in vivo antitumour activity. (1980) (17)
The possible role of electron-transfer complexes in the antitumour action of amsacrine analogues. (1990) (17)
Short-term cultures of clinical tumor material: potential contributions to oncology research. (1999) (17)
Induction of petite formation in Saccharomyces cerevisiae by experimental antitumour agents. Structure--activity relationships for 9-anilinoacridines. (1981) (17)
Verapamil modulates mutagenicity of antitumour acridines in bacteria and yeast. (1986) (17)
Potential Antitumor Agents. Part 61. Structure-Activity Relationships for in vivo Colon 38 Activity Among Disubstituted 9-Oxo-9H-xanthene-4- acetic Acids. (1991) (17)
Synthesis, DNA interactions and biological activity of DNA minor groove targeted polybenzamide-linked nitrogen mustards. (1995) (17)
Effect of 3-fluorothalidomide and 3-methylthalidomide enantiomers on tumor necrosis factor production and antitumor responses to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). (2003) (16)
Synthesis and biological evaluation of sulfonamide analogues of the phosphatidylinositol 3-kinase inhibitor ZSTK474. (2017) (16)
Preclinical efficacy of vascular disrupting agents in non-small-cell lung cancer. (2011) (16)
Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance. (1990) (16)
Plasma half-life of cytosine arabinoside (NSC-63878) in patients treated for acute myeloblastic leukemia. (1971) (16)
Comparison of the mutagenicity of amsacrine with that of a new clinical analogue, CI-921. (1988) (16)
Derivatives of amsacrine: determinants required for high activity against Lewis lung carcinoma. (1988) (16)
POTENTIAL ANTITUMOR AGENTS. PART 43. SYNTHESIS AND BIOLOGICAL ACTIVITY OF DIBASIC 9-AMINOACRIDINE-4-CARBOXAMIDES, A NEW CLASS OF ANTITUMOR AGENT (1985) (16)
Cytokinetic factors in drug resistance of Lewis lung carcinoma: comparison of cells freshly isolated from tumours with cells from exponential and plateau-phase cultures. (1987) (15)
Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal scheduling. (2003) (15)
Necrosis in non-tumour tissues caused by flavone acetic acid and 5,6-dimethyl xanthenone acetic acid. (1990) (15)
A comparison of the effects of aphidicolin and other inhibitors on topoisomerase II-directed cytotoxic drugs. (1993) (15)
ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy. (2010) (15)
Physicochemical characterization of asulacrine towards the development of an anticancer liposomal formulation via active drug loading: stability, solubility, lipophilicity and ionization. (2014) (15)
Transient retinal effects of 5,6-dimethylxanthenone-4-acetic acid (DMXAA, ASA404), an antitumor vascular-disrupting agent in phase I clinical trials. (2009) (15)
Electron donor properties of the antitumour drug amsacrine as studied by fluorescence quenching of DNA-bound ethidium. (1987) (15)
Structure-activity studies of amsacrine analogs in drug resistant human leukemia cell lines expressing either altered DNA topoisomerase II or P-glycoprotein. (1992) (15)
CHAPTER 15 – TUMOR CELL CULTURES IN DRUG DEVELOPMENT (2002) (15)
Nucleic acid binding drugs--XIV. The crystal structure of 1-methyl amsacrine hydrochloride; relationships to DNA-binding ability and anti-tumour activity. (1986) (15)
Induction of petite mutants in yeast by non-intercalative DNA-binding antitumour agents. (1983) (14)
Mutagenicity profiles of newer amsacrine analogues with activity against solid tumours: comparison of microbial and mammalian systems. (1989) (14)
Using a stem cell and progeny model to illustrate the relationship between cell cycle times of in vivo human tumour cell tissue populations, in vitro primary cultures and the cell lines derived from them. (2009) (14)
Acridine-based Anticancer Drugs (1994) (14)
Potential antitumor agents. 37. Organophosphorus derivatives of 9-anilinoacridine. (1982) (14)
Synthesis and cytotoxic activity of N-(2-diethylamino)ethylcarboxamide and other derivatives of 10H-quindoline. (2002) (14)
Resistance mechanisms to topoisomerase poisons: the application of cell culture methods. (1992) (14)
Nitric oxide: its production in host-cell-infiltrated EMT6 spheroids and its role in tumour cell killing by flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid (2004) (14)
Potential antitumor agents. 47. 3'-Methylamino analogues of amsacrine with in vivo solid tumor activity. (1986) (13)
Increased paired box transcription factor 8 has a survival function in Glioma (2014) (13)
Comparative biodistribution and metabolism of carbon-11-labeled N-[2-(dimethylamino)ethyl]acridine-4-carboxamide and DNA-intercalating analogues. (2001) (13)
Induction of natural killer activity by xanthenone analogues of flavone acetic acid: relation with antitumour activity. (1991) (13)
Centrosomal dysregulation in human metastatic melanoma cell lines. (2011) (13)
Potential antitumor agents. 48. 3'-Dimethylamino derivatives of amsacrine: redox chemistry and in vivo solid tumor activity. (1987) (13)
Proliferative assays for the assessment of radiosensitivity of tumor cell lines using 96-well microcultures (1993) (13)
Mathematical Determination of Cell Population Doubling Times for Multiple Cell Lines (2012) (13)
Inhibition of DMXAA-induced tumor necrosis factor production in murine splenocyte cultures by NF-kappaB inhibitors. (2006) (13)
In vitro methods for screening agents with an indirect mechanism of antitumour activity: xanthenone analogues of flavone acetic acid. (1991) (13)
Hyporesponsiveness of macrophages from C3H/HeJ (endotoxin-resistant) mice to the antitumour agent flavone acetic acid (NSC 347512). (1989) (13)
NF-kappaB-independent induction of endothelial cell apoptosis by the vascular disrupting agent DMXAA. (2007) (13)
Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide (2008) (13)
Inverse correlation between bacterial frameshift mutagenicity and yeast mitochondrial effects of antitumour anilinoacridines. (1985) (13)
Derivation of Breast Cancer Cell Lines Under Physiological (5%) Oxygen Concentrations (2018) (13)
Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIα and β (1999) (13)
DNA-Binding Anticancer Drugs: One Target, Two Actions (2021) (13)
Optimization of an ICP-MS assay for the detection of trace levels of platinum in peripheral nerves (1998) (13)
The Genes of Life and Death: A Potential Role for Placental‐Specific Genes in Cancer (2017) (12)
Beta adrenergic regulation of glycogen phosphorylase activity and adenosine cyclic 3', 5'-monophosphate accumulation in control and desensitized C-6 astrocytoma cells. (1977) (12)
The role of topoisomerases and RNA transcription in the action of the antitumour benzonaphthyridine derivative SN 28049 (2008) (12)
Potential antitumor agents. 41. Analogues of amsacrine with electron-donor substituents in the anilino ring. (1984) (12)
Protection by inhibitors of multidrug resistance against mitochondrial mutagenesis in Saccharomyces cerevisiae. (1990) (12)
Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK (2021) (12)
Neuroprotective interactions in rats between paclitaxel and cisplatin. (2000) (12)
Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide (2011) (12)
Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. (2003) (12)
Differential growth inhibition of cultured mammalian cells: comparison of clinical antitumour agents and amsacrine derivatives. (1984) (12)
Steric constraints for DNA binding and biological activity in the amsacrine series. (1986) (12)
Carbon-11 labelling of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and determination of plasma metabolites in man. (1997) (12)
Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA). (2001) (12)
Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor (2004) (12)
A comparison of the ability of DMXAA and xanthenone analogues to activate NF-kappaB in murine and human cell lines. (2005) (12)
Uptake of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and activation of NF-kappaB in human tumor cell lines. (2002) (12)
Relationship of cell cycle parameters to in vitro and in vivo chemosensitivity for a series of Lewis lung carcinoma lines. (1992) (12)
Interaction of nucleic acids with a non-intercalative anti-leukemic compound containing bisquarternary heterocycles. (1984) (12)
'Minimal' DNA-intercalating agents as anti-tumour drugs: 2-styrylquinoline analogues of amsacrine. (1987) (12)
Cytokinetic resistance of Lewis lung carcinoma to cyclophosphamide and the amsacrine derivative CI-921. (1986) (11)
Reduction of cytotoxic effector cell activity in colon 38 tumours following treatment with flavone acetic acid. (1989) (11)
A comparison of the requirements for antitumour activity and antibacteriophage lambda activity for a series of non-intercalative DNA-binding agents. (1982) (11)
Cellular uptake of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA). (1999) (11)
Cellular responses to methyl-N-[4-9-acridinylamino)-2-methoxyphenyl] carbamate hydrochloride, an analogue of amsacrine active against non-proliferating cells. (1997) (11)
A phase I trial of amsalog (CI-921) administered by intravenous infusion using a 5-day schedule (2001) (11)
Retrotransposon Hypomethylation in Melanoma and Expression of a Placenta-Specific Gene (2014) (11)
A carbamate analogue of amsacrine with activity against non-cycling cells stimulates topoisomerase II cleavage at DNA sites distinct from those of amsacrine. (1997) (11)
Classical and Targeted Anticancer Drugs: An Appraisal of Mechanisms of Multidrug Resistance. (2016) (11)
Multiseed liposomal drug delivery system using micelle gradient as driving force to improve amphiphilic drug retention and its anti-tumor efficacy (2018) (11)
A mathematical model for analysis of the cell cycle in human tumour (2002) (11)
Unusual dynamics of killing of cultured lewis lung cells by the DNA-intercalating antitumour agentN-[2-(dimethylamino)ethyl]acridine-4-carboxamide (2004) (11)
Comparison of transfer RNA and aminoacyl RNA ligases from calf liver and spleen. (1966) (11)
Determination of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide in Caco-2 monolayers by liquid chromatography with fluorescence detection: application to transport studies. (2004) (11)
Experimental antitumor activity of the amsacrine analogue CI-921. (1987) (10)
Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs (2009) (10)
Cytokinetic differences in the action ofN-[2-(dimethylamino)ethyl]acridine-4-carboxamide as compared with that of amsacrine and doxorubicin (2004) (10)
Improving drug retention in liposomes by aging with the aid of glucose. (2016) (10)
Localization of a nonintercalative DNA binding antitumour drug in mitochondria: relationship to multidrug resistance. (1989) (10)
Structure-activity relationships for substituted 9-oxo-9,10-dihydroacridine-4-acetic acids: analogues of the colon tumour active agent xanthenone-4-acetic acid. (1992) (10)
Estimation of radiation-induced interphase cell death in cultures of human tumor material and in cell lines. (2004) (10)
Sequence-specific binding of antitumour bisquaternary ammonium heterocycles to DNA and inhibition of polymerase activity in vitro. (1996) (10)
Exploring the isoform selectivity of TGX-221 related pyrido[1,2-a]pyrimidinone-based Class IA PI 3-kinase inhibitors: synthesis, biological evaluation and molecular modelling. (2015) (10)
The paradox of cancer cell apoptosis. (2011) (10)
Photo-enhancement of the mutagenicity of 9-anilinoacridine derivatives related to the antitumour agent amsacrine. (1992) (10)
Therapeutic reactivation of mutant p53 protein by quinazoline derivatives (2012) (10)
Anticancer potential of tumor vascular disrupting agents: review of the latest clinical evidence (2012) (10)
Selected GRIN2A mutations in melanoma cause oncogenic effects that can be modulated by extracellular glutamate. (2016) (10)
Identification of cyclohexanone derivatives that act as catalytic inhibitors of topoisomerase I: effects on tamoxifen-resistant MCF-7 cancer cells (2011) (10)
DNA binding and growth inhibitory properties of a series of 2,7-di-alkyl-substituted derivatives of proflavine. (1982) (9)
Novel Strategies for Overcoming Multidrug Resistance in Cancer (2012) (9)
The immunological status of mice during the generation of cyclophosphamide-induced tolerance. (1976) (9)
Genetic toxicology of tricyclic carboxamides, a new class of DNA binding antitumour agent. (1990) (9)
Synthesis and Antitumor Properties of N‐(2‐(Dimethylamino)ethyl) carboxamide Derivatives of Fused Tetracyclic Quinolines and Quinoxalines: A New Class of Putative Topoisomerase Inhibitors. (1997) (9)
PIK3CA‐mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation (2017) (9)
Synthesis, DNA binding interactions and biological activity of bis platinum (II) complexes of N,N,N',N'-tetrakis(2-aminoethyl)diamines. (1992) (9)
Pharmacokinetics and distribution of SN 28049, a novel DNA binding anticancer agent, in mice (2010) (9)
Binding of nonintercalative antitumor drugs to DNA-polymers: structural effects of bisquaternary ammonium heterocycles. (1987) (9)
5,7-Disubstituted analogues of the mixed topoisomerase I/II poison N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA): DNA binding and patterns of cytotoxicity. (1999) (9)
Analysis of radiation‐induced changes to human melanoma cultures using a mathematical model (2010) (8)
Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agent (2014) (8)
DNA binding of the nonintercalative ligands SN-6132, SN-6131 and SN-6113: minor variations of the ligand structure may cause changes in the base pair preference. (1992) (8)
Comparison of the cytotoxicity of amsacrine and its analogue CI-921 against cultured human and mouse bone marrow tumour cells. (1990) (8)
Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of colon 38 tumours (2004) (8)
Potential antitumor agents. 42. Structure-activity relationships for acridine-substituted dimethyl phosphoramidate derivatives of 9-anilinoacridine. (1984) (8)
Selective antitumour activity of metal complexes of bidentate pyridylphosphines (1997) (8)
Establishment of primary human meningiomas as subcutaneous xenografts in mice. (2001) (8)
THIOLYTIC CLEAVAGE AND BINDING OF THE ANTITUMOUR AGENT CI-921 IN BLOOD (1988) (8)
Comparison of in vivo and in vitro drug sensitivities of Lewis lung carcinoma and P388 leukaemia to analogues of amsacrine. (1987) (8)
Flavone acetic acid and 5,6-dimethylxanthenone-4-acetic acid: relationship between plasma nitrate elevation and the induction of tumour necrosis. (1993) (8)
A rapid LC-MS/MS method for the quantitation of a series of benzonaphthyridine derivatives: application to in vivo pharmacokinetic and lipophilicity studies in drug development. (2012) (8)
Genomic and signalling pathway characterization of the NZM panel of melanoma cell lines: A valuable model for studying the impact of genetic diversity in melanoma (2020) (8)
Synthesis and biological evaluation of phenanthrene-derived carboxamides as cytotoxic agents. (1993) (7)
The use of human tumour cell lines in the discovery of new cancer chemotherapeutic drugs (2008) (7)
Novel pyrazolo[1,5-a]pyridines with improved aqueous solubility as p110α-selective PI3 kinase inhibitors. (2017) (7)
Selective inhibition of the growth of bacteriophage lambda by experimental antileukaemic bisquaternary salts. (1974) (7)
Potential Antitumor Agents. Part 57. 2‐Phenylquinoline‐8‐carboxamides as “Minimal” DNA‐Intercalating Antitumor Agents with in vivo Solid Tumor Activity. (1989) (7)
Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. (2003) (7)
Novel pyrazolo[1,5-a]pyridines as PI3K inhibitors: variation of the central linker group (2014) (7)
Synthesis and biological evaluation of solubilized sulfonamide analogues of the phosphatidylinositol 3-kinase inhibitor ZSTK474. (2019) (7)
Origin of transfer RNA. (1966) (7)
Comparison of Global DNA Methylation Patterns in Human Melanoma Tissues and Their Derivative Cell Lines (2021) (7)
Modulation of superoxide production from murine macrophages by the antitumour agent flavone acetic acid and xanthenone acetic acid analogues. (1992) (6)
Relationship between the structure of analogues of amsacrine and their degree of cross-resistance to adriamycin-resistant P388 leukaemia cells. (1988) (6)
Comparison of a homologous series of benzonaphthyridine anti-cancer agents in mice: divergence between tumour and plasma pharmacokinetics (2012) (6)
Inhibition of restriction endonucleases by DNA sequence‐reading ligands (1996) (6)
Development and validation of bioanalytical method for the determination of asulacrine in plasma by liquid chromatography. (2008) (6)
Inhibition of antitumor effects of flavone acetic acid by cortisone. (1993) (6)
Synthesis, biological evaluation and molecular modelling of sulfonohydrazides as selective PI3K p110alpha inhibitors. (2007) (6)
Validating TDP1 as an Inhibition Target for the Development of Chemosensitizers for Camptothecin-Based Chemotherapy Drugs (2021) (6)
Development and validation of a liquid chromatography-mass spectrometry (LC-MS) assay for the determination of the anti-cancer agent N-[2-(dimethylamino)ethyl]-2,6-dimethyl-1-oxo-1,2-dihydrobenzo[b]-1,6-naphthyridine-4-carboxamide (SN 28049). (2008) (6)
9-Anilinoacridines: novel compounds active against herpes simplex virus. (1985) (6)
Small-molecule cytokine inducers causing tumor necrosis. (2001) (6)
Effect of tumour growth on the macrophage response to the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. (1993) (5)
Amsacrine analogues with extended chromophores: DNA binding and anti-tumour activity. (1987) (5)
Determination of xanthenone-4-acetic acid in mouse plasma by high-performance liquid chromatography. (1991) (5)
In vitro and in vivo assessment of activity of new anilino-substituted analogues of amsacrine against Lewis lung carcinoma. (1986) (5)
In vivo and in vitro assessment of the action of SN 28049, a benzonaphthyridine derivative targeting topoisomerase II, on the murine Colon 38 carcinoma (2011) (5)
Flavones and Xanthenones as Vascular‐disrupting Agents (2006) (5)
Determination of the activation spectrum of aluminium phthalocyanine chloride against cultured meningioma cells using a tunable laser (1996) (5)
Low-molecular-weight T4 phage-specific RNA. (1967) (5)
Induction of mitotic crossing-over by the topoisomerase II poison DACA (N-[2-dimethylamino)ethyl]acridine-4-carboxamide) in Saccharomyces cerevisiae. (1993) (5)
96 POSTER Potential importance of the ceramide pathway in the action of the tumour vascular disrupting agent ASA404 (DMXAA, 5,6-dimethylxanthenone-4-acetic acid) (2008) (4)
Tumour tissue selectivity in the uptake and retention of SN 28049, a new topoisomerase II-directed anticancer agent (2013) (4)
Disposition of the novel antitumour agent xanthenone-4-acetic acid in the mouse: identification of metabolites and routes of elimination. (1994) (4)
DNA-Directed Alkylating Agents. 6. Synthesis and Antitumor Activity of DNA Minor Groove-Targeted Aniline Mustard Analogs of Pibenzimol. [Erratum to document cited in CA121:300815] (1995) (4)
Cell cycling, cdc2, and cancer. (1991) (4)
Effects of CI-921, an analogue of amsacrine, on advanced Lewis lung tumours in mice: relevance to clinical trials. (1988) (4)
Modelling the flow [corrected] cytometric data obtained from unperturbed human tumour cell lines: parameter fitting and comparison. (2005) (4)
Relationship between the induction of chromosome damage and cytotoxicity for amsacrine and congeners. (1984) (4)
Sequence‐specific interactions of minor groove binders with restriction fragments of cDNAs for H tau 40 protein and MAP kinase 2. A qualitative and quantitative footprinting study (1999) (4)
Structure-dependent effects of minor groove binders on the DNA triple helix motif poly(dA).2poly(dT): influence of antitumoractive nonintercalative bisquaternary ammonium heterocycles. (1998) (4)
Plasma levels of 5-hydroxyindole-3-acetic acid (5HIAA) as a pharmacodynamic marker of blood flow changes induced by the vascular targeting agent (VTA) 5,6 dimethyl xanthenone acetic acid, DMXAA (2005) (4)
Cultures of Surgical Material from Lung Cancers (2003) (4)
Preliminary Evidence That High-Dose Vitamin C has a Vascular Disrupting Action in Mice (2014) (4)
The role of immune effector cells in flavone acetic acid-induced injury to tumor cells in EMT6 spheroids. (1992) (3)
Sequence Specific Modulation of DNA Restriction Enzyme Cleavage by Minor Groove Binders (1998) (3)
DNA-Directed Alkylating Agents. Part 4. 4-Anilinoquinoline-Based Minor Groove Directed Aniline Mustards. (1991) (3)
Abstract 1660: The antitumor action of ASA404 (vadimezan; DMXAA); potential involvement of vascular endothelial growth factor (VEGF) (2010) (3)
POTENTIAL ANTITUMOR AGENTS. 40. ORALLY ACTIVE 4,5-DISUBSTITUTED DERIVATIVES OF AMSACRINE (1984) (3)
Regulation of protein biosynthesis (1966) (3)
Autophagy mediated danger signaling regulates tumor immunosurveillance and may potentiate the effects of anti-cancer immunotherapy through increased adjuvanticity (2020) (3)
Flavone-8-acetic Acid and Xanthenone-4-acetic Acid Macrophages Treated with the Antitumor Agents Evidence for the Production of Nitric Oxide by Activated Updated (2006) (3)
Electron-Deficient DNA-Intercalating Agents as Antitumor Drugs: Aza Analogues of the Experimental Clinical Agent N-(2-(Dimethylamino)ethyl) acridine-4-carboxamide. (1994) (3)
The ubiquitin-proteasome system is inhibited by p53 protein expression in human ovarian cancer cells. (2010) (3)
Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta. (1999) (3)
[88] The hot DEAE-column method for transfer RNA fractionation (1967) (3)
Haematological effects in mice of the antitumour agents xanthenone-4-acetic acid, 5,6-methyl-xanthenone-4-acetic acid and flavone acetic acid (2004) (3)
Genome-wide DNA methylation and RNA expression differences correlate with invasiveness in melanoma cell lines. (2021) (3)
Potential Antitumor Agents. Part 62. Structure‐Activity Relationships for Tricyclic Compounds Related to the Colon Tumor Active Drug 9‐Oxo‐ 9H‐xanthene‐4‐acetic Acid. (1991) (2)
149 Inhibition of vasculogenic mimicry in melanoma by the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA) (2004) (2)
Do negative feedback oscillations drive variations in the length of the tumor cell division cycle? (2005) (2)
POTENTIAL ANTITUMOR AGENTS. 39. ANILINO RING GEOMETRY OF AMSACRINE AND DERIVATIVES: RELATIONSHIP TO DNA BINDING AND ANTITUMOR ACTIVITY (1984) (2)
ASA404 (DMXAA): New Concepts in Tumour Vascular Targeting Therapy (2010) (2)
Cultures of surgical material from lung cancers. A kinetic approach. (2003) (2)
Abstract 4443: Molecular mechanistic study of ASA404 (vadimezan)-induced endothelial cell death (2010) (2)
Potential Antitumor Agents. Part 46. Structure-Activity Relationships for Acridine Monosubstituted Derivatives of the Antitumor Agent N-[2-(Dimethylamino)ethyl]-9-aminoacridine-4-carboxamide. (1986) (2)
Schedule dependence of activity of the amsacrine analogue CI-921 towards P388 leukaemia and Lewis lung carcinoma. (1985) (2)
Abstract 1644: Design and discovery of PWT33597 (VDC-597), a dual inhibitor of PI3-kinase alpha and mTOR (2014) (2)
Inhibition of tumor blood flow. (2000) (2)
Novel carbamate analogues of amsacrine with activity against non-cycling murine and human tumour cells (2004) (2)
The relationship between lipophilic-hydrophilic balance, uptake and anti-bacteriophage lambda activity of experimental anti-tumour bisquaternary salts. (1988) (2)
The synthesis, stability and biological activity of bis-intercalating bis-daunomycin hydrazones. (1990) (2)
Stimulation of bacterial mutagenicity by inhibitors of mammalian cell multidrug resistance. (1991) (2)
Splenic foci of cytotoxic lymphocytes in a graft-versus-host reaction. (1978) (2)
POTENTIAL ANTITUMOR AGENTS. PART 28. DEOXYRIBONUCLEIC ACID POLYINTERCALATING AGENTS (1978) (2)
SOX2OT Long Noncoding RNA Is Regulated by the UPR in Oestrogen Receptor-Positive Breast Cancer (2020) (1)
Potential Antitumor Agents. Part 50. In vivo Solid-Tumor Activity of Derivatives of N-(2-(Dimethylamino)ethyl)acridine-4-carboxamide. (1987) (1)
Targeting Axl: a potential therapy for glioblastoma (2017) (1)
412P Effects of statins on melanoma (2016) (1)
Cytotoxic and DNA binding properties of aminoalkyl derivatives of di- and triazaphenanthrenes. (1992) (1)
Correction: Sarkar, D., et al. Multiple Isoforms of ANRIL in Melanoma Cells: Structural Complexity Suggests Variations in Processing. Int. J. Mol. Sci. 2017, 18, 1378 (2018) (1)
Effect of SFX-01 on proliferation of human glioblastoma cell lines (2021) (1)
POTENTIAL ANTITUMOR AGENTS. PART 38. 3-SUBSTITUTED 5-CARBOXAMIDO DERIVATIVES OF AMSACRINE (1984) (1)
Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines (2012) (1)
Stem Cell Niche Versus Cancer Stem Cell Niche – Differences and Similarities (2009) (1)
Cis-Diammineplatinum(II) Complexes Tethered to DNA-Affinic Ligands: Antitumour Activity and DNA-Binding Properties (1991) (1)
Chemistry of the Podocarpaceae. XLI. The decarbonylation of 12-Methoxypodocarpa-8,11,13-trien-19-oic acid and Abieta-8,11,13-trien-18-oic acid (1972) (1)
Additional file 10: Figure S8. of ZFAS1: a long noncoding RNA associated with ribosomes in breast cancer cells (2016) (1)
Phase I Trial of the Amsacrine Analogue (2006) (1)
Haematological effects in mice of the antitumour agents xanthenone-4-acetic acid, 5,6-dimethyl-xanthenone-4-acetic acid [correction of 5,6-methyl-] and flavone acetic acid. (1991) (1)
Potential Antitumor Agents. Part 45. Synthesis, DNA-Bindung Interaction and Biological Activity of Triacridine Derivatives. (1986) (1)
Sequence‐specific interactions of minor groove binders with the 154 base pair hindlll‐rsal restriction fragment of cDNA of the human tau 40 protein involved in pathology of alzheimer's disease (1997) (1)
Additional file 1: Figure S1. of ZFAS1: a long noncoding RNA associated with ribosomes in breast cancer cells (2016) (0)
Potential Antitumor Agents. Part 48. 3′-Dimethylamino Derivatives of Amsacrine (I): Redox Chemistry and in vivo Solid Tumor Activity. (1987) (0)
phenyljamino^A^S-dimethyM-acridinecarboxamide(CI-921y (1988) (0)
The Kinetics of 9-[[2-Methoxy-4[(methyl-Sulphonyl)amino]phenyl] Amino]-N, 5-Dimethyl-4-Acridinecarboxamide (ci-921) in a Phase-Ii Study (1989) (0)
Additional file 14: Figure S11. of ZFAS1: a long noncoding RNA associated with ribosomes in breast cancer cells (2016) (0)
POTENTIAL ANTITUMOR AGENTS. 41. ANALOGS OF AMSACRINE WITH ELECTRON-DONOR SUBSTITUENTS IN THE ANILINO RING (1984) (0)
Mutagenic potency and drug structure in some experimental anti-cancer drugs (1980) (0)
DNA-intercalating Analogues [ 2-( Dimethylamino ) ethyl ] acridine-4-carboxamide and N-Carbon-11-labeled Comparative Biodistribution and Metabolism of Updated Version (2001) (0)
Abstract A09: Cooperation of the MAPK and PI3K>AKT>mTORC1 signaling pathways is required for PIK3CA mutant melanoma maintenance (2015) (0)
Topoisomerases and cancer treatment. (1991) (0)
POTENTIAL ANTITUMOR AGENTS. 37. ORGANOPHOSPHORUS DERIVATIVES OF 9-ANILINOACRIDINE (1983) (0)
Modulation of Protein-DNA Interactions by Intercalating and Nonintercalating Agents (1990) (0)
Potential Antitumor Agents. Part 44. Synthesis and Antitumor Activity of New Classes of Diacridines: Importance of Linker Chain Rigidity for DNA Binding Kinetics and Biological Activity. (1986) (0)
Additional file 12: Table S3. of ZFAS1: a long noncoding RNA associated with ribosomes in breast cancer cells (2016) (0)
Epigenetics in Melanoma (2018) (0)
Contents, Vol. 41, 1971 (1971) (0)
Evidence that phospholipase C is involved in the antitumour action of NSC768313, a new thieno[2,3-b]pyridine derivative (2016) (0)
POTENTIAL ANTITUMOR AGENTS. 35. QUANTITATIVE RELATIONSHIPS BETWEEN ANTITUMOR (L1210) POTENCY AND DNA BINDING FOR 4′‐(9‐ACRIDINYLAMINO)METHANESULFON‐M‐ANISIDIDE (M‐AMSA) ANALOGS (1981) (0)
Additional file 8: Figure S7. of ZFAS1: a long noncoding RNA associated with ribosomes in breast cancer cells (2016) (0)
POTENTIAL ANTITUMOR AGENTS. 42. STRUCTURE-ACTIVITY RELATIONSHIPS FOR ACRIDINE-SUBSTITUTED DIMETHYL PHOSPHORAMIDATE DERIVATIVES OF 9-ANILINOACRIDINE (1985) (0)
Pyrazolo[1,5-a]pyridines: alpha-isoform-selective inhibitors of phosphatidylinositol-3-kinase (PI3K) (2009) (0)
P-5-600 Meningiomas: Prognostic markers for recurrence (1997) (0)
Bruce F. Cain 1930-1981 (1981) (0)
A Feasibility Study of Magnesium Supplementation for Cognitive Impairment from Adjuvant Endocrine Therapy for Breast Cancer (2017) (0)
POTENTIAL ANTITUMOR AGENTS. 29. QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS S FOR THE ANTILEUKEMIC BISQUATERNARY AMMONIUM HETEROCYCLES (1979) (0)
Traitement combine contre le cancer (2001) (0)
Additional file 11: Figure S9. of ZFAS1: a long noncoding RNA associated with ribosomes in breast cancer cells (2016) (0)
The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfonylamino)phenylamino]-4-acridinecarboxamide (CI-921) in a phase 1 trial (2004) (0)
Additional file 2: Figure S2. of ZFAS1: a long noncoding RNA associated with ribosomes in breast cancer cells (2016) (0)
Cell cycling, cdc2 and cancer (1992) (0)
Potential Antitumor Agents. Part 49. 5-Substituted Derivatives of N-(2- (Dimethylamino)ethyl)-9-aminoacridine-4-carboxamide with in vivo Solid- Tumor Activity. (1987) (0)
Mathematical Determination of Cell Population Doubling Times for Multiple Cell Lines (2012) (0)
ZFAS1: a long noncoding RNA associated with ribosomes in breast cancer cells (2016) (0)
Substituted o phenylenediamine acridine compounds having antitumor activity us patent 4603125. july 29 1986 (1986) (0)
Potential Antitumor Agents. Part 58. Synthesis and Structur-Activity Relationships of Substituted Xanthenone-4-acetic Acids Active Against the Colon 38 Tumor in vivo. (1989) (0)
138 Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by co-administration of non-steroidal anti-inflammatory drugs (2004) (0)
Anticancer preparation comprising DMXAA (2003) (0)
United States Patent ( 19 ) Rewcastle et al . ( 54 ) CERTAIN ACRDNYL-PHOSPHORAMDATE COMPOUNDS (2017) (0)
Additional file 6: Figure S5. of ZFAS1: a long noncoding RNA associated with ribosomes in breast cancer cells (2016) (0)
Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK (2021) (0)
Assessment of the action of a new DNA-targeting agent, SN 28049 in two novel murine cell lines (2007) (0)
Potential Antitumor Agents. Part 59. Structure-Activity Relationships for 2-Phenylbenzimidazole-4-carboxamides, a New Class of “Minimal” DNA-Intercalating Agents which May not Act via Topoisomerase II. (1990) (0)
Abstract 29: MEK and PI3K signaling cooperate through mTORC1/2 to promote PIK3CA mutant melanoma cell proliferation (2016) (0)
COMPRISING A COX-2 INHIBITOR (2017) (0)
Potential Antitumor Agents. Part 51. Synthesis and Antitumor Activity of Substituted Phenazine-1-carboxamides. (1987) (0)
Additional file 16: Figure S13. of ZFAS1: a long noncoding RNA associated with ribosomes in breast cancer cells (2016) (0)
Potential Antitumor Agents. Part 47. 3′-Methylamino Analogues of Amsacrine with in vivo Solid Tumor Activity. (1987) (0)
The potential of molecular and cellular biology. (1988) (0)
New Biopharmaceutical: SN 28049 commercialisation plan (2016) (0)
Fractionation of amino acid acceptor ribonucleic acid. 3. (1965) (0)
Population pharmacokinetics (PK) of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in cancer patients. (2006) (0)
In vivo and in vitro assessment of the action of the antitumour benzonaphthyridine derivative SN 28049 on the murine Colon 38 (2010) (0)
megakaryocyte regulatory pathway mediated by Nmda receptors : Pb 3.29–3 (2013) (0)
Population Pharmacokinetic-Pharmacodynamic Model of the Vascular-DisruptingAgent 5,6-Dimethylxanthenone-4-Acetic Acid inCancer Patients (2008) (0)
Regression Analysis of 4′-(9-Acridinylamino) Methanesulphon-m-Anisidide (m-AMSA) Analogue Properties Providing High Dose-Potency in Leukaemia L1210 Assays (1980) (0)
Strategies to Maximize Liposomal Drug Loading for a Poorly Water-soluble Anticancer Drug (2014) (0)
Compounds with anti-tumor and anti-bacterial properties. (1987) (0)
Plateau-Phase Chinese Hamster Fibroblast Cell Cultures Uptake , Metabolism , and DNA Breakage in Log-and-anisidide : Comparison of m-( 9-Acridinylamino ) methanesulfon-′ Mechanism of Resistance of Noncycling Mammalian Cells to 4 Updated (2006) (0)
Therapeutic targeting of tumor angiogenesis: how far have we come? (2014) (0)
Additional file 7: Figure S6. of ZFAS1: a long noncoding RNA associated with ribosomes in breast cancer cells (2016) (0)
Strategies to improve Asulacrine retention within liposomes with DPPG and loading by glutathione gradient (2017) (0)
Increased paired box transcription factor 8 has a survival function in Glioma (2014) (0)
In vitro studies of bidentate pyridyl phosphine gold(I) and silver(I) complexes as potential antitumour agents in ovarian tumor cell lines and isolated hepatocytes (2005) (0)
Optimization of Weight Ratio for DSPE-PEG/TPGS Hybrid Micelles to Improve Drug Retention and Tumor Penetration (2018) (0)
Additional file 5: Figure S4. of ZFAS1: a long noncoding RNA associated with ribosomes in breast cancer cells (2016) (0)
Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer (2020) (0)
Studies on Nucleic Acids in Relation to Protein Synthesis (1966) (0)
Additional file 15: Figure S12. of ZFAS1: a long noncoding RNA associated with ribosomes in breast cancer cells (2016) (0)
11 Heterogeneity of Phenotype in Breast Cancer Cell Lines (2017) (0)
Arabinoside in Patients with "IT "1" Leukaemia--the Effect of urlalne (1975) (0)
This study was conducted under the auspices of the Cancer Research Campaign's Phase I/II Committee (1999) (0)
Additional file 13: Figure S10. of ZFAS1: a long noncoding RNA associated with ribosomes in breast cancer cells (2016) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Bruce Charles Baguley?

Bruce Charles Baguley is affiliated with the following schools:

University of Auckland

Bruce Charles Baguley's Academic­Influence.com Rankings

Bruce Charles Baguley's Degrees

Why Is Bruce Charles Baguley Influential?

Bruce Charles Baguley's Published Works

Published Works

What Schools Are Affiliated With Bruce Charles Baguley?

Bruce Charles Baguley's AcademicInfluence.com Rankings